Using the electronic medical records to identify patients with hypertension in primary care: A validation study using EMRALD.

Size: px
Start display at page:

Download "Using the electronic medical records to identify patients with hypertension in primary care: A validation study using EMRALD."

Transcription

1 Using the electronic medical records to identify patients with hypertension in primary care: A validation study using EMRALD. Noah Ivers, Bogdan Pylypenko, Karen Tu CAHSPR: May 10, 2011

2 Acknowledgements No Conflicts of Interest This project was supported by team grant from CIHR: The Canadian Cardiovascular Outcomes Research Team NI is supported by a CIHR Fellowship in Clinical Research and a Fellowship from the Department of Family and Community Medicine, University of Toronto KT is supported by a CIHR Fellowship in Primary Care Research and is a Research Scholar with the Department of Family and Community Medicine, University of Toronto

3 EMR: Promise versus Practice

4 Clinical Problem: Hypertension Canadian prevalence: 23% of adults in 2006 Public Health Agency of Canada, using CCDSS data files 7% of office visits to Canadian physicians in 2005 Hemmelgarn et al. Can J Cardiol June; 24(6): % of hypertension is untreated Mohan et al. Can J Cardiol Oct;26(8): Treating hypertension reduces CV outcomes Staessen et al. Lancet 2001;358:

5 Objectives To validate methods for identifying patients with HTN within the EMR Compare EMR-based searches of past medical history fields, BP measurements, billing data, etc. Discuss strengths and weaknesses of different approaches

6 Setting: EMRALD

7 Age Groups (Years) Age Groups (Years) Setting: EMRALD > 100 FPs, > 120,000 patients Ontario Population 2007 EMR Population Distribution % -4.00% -2.00% 0.00% 2.00% 4.00% 6.00% Percent Male Female % -4.00% -2.00% 0.00% 2.00% 4.00% 6.00% Percent Male Female

8 Methods Manual Abstraction 5% random sample from 17 FPs Three trained nurse abstractors Clinical history: physician diagnosis in medical history, visit notes, consultation letters, discharge summaries, diagnostic tests elevated BP and an antihypertensive prescription on the same day

9 Methods Reference Standard Add BP measurements for unrecognized patients CHEP diagnostic criteria, any of the following: Any Diastolic >120mmHg Two consecutive readings of systolic > 140mmHg or diastolic > 90mmHg for patients with diabetes, chronic kidney disease, or CVD. Systolic >180mmHg or diastolic >110mmHg, with previous measurement of systolic >140mmHg or diastolic >90mmHg Three consecutive measurements averaging systolic >160mmHg or diastolic >100mmHg, after a reading of systolic >140mmHg or diastolic >90mmHg Five consecutive visits with an average systolic >140mmHg or diastolic >90mmHg after a reading of systolic >140mmHg or diastolic >90mmHg (including the initial elevated BP reading).

10 Results - Participants 969 Patients: 49 years old (SD 17), 54% female # HTN from manual chart abstraction: 263 Chart abstraction Kappa > 0.80 # HTN from chart abstraction + CHEP: 300 Total prevalence of HTN in random sample = 31% (unrecognized, untreated = 37/969, 3.8%)

11 Results - Validation Sensitivity Specificity PPV NPV Past Medical Hx (CPP) search 43.3% 96.3% 83.9% 79.1%

12 Results - Validation Sensitivity Specificity PPV NPV Past Medical Hx (CPP) search 43.3% 96.3% 83.9% 79.1% BP measurements: Ever >140/ % 74.9% 61.0% 93.1% >140/90 x2 in 1 year 75.0% 95.1% 87.2% 89.5% >140/90 x3 in 3 years 67.3% 98.2% 94.4% 87.0%

13 Results - Validation Sensitivity Specificity PPV NPV Past Medical Hx (CPP) search 43.3% 96.3% 83.9% 79.1% BP measurements: >140/90 ever 87.7% 74.9% 61.0% 93.1% >140/90 x2 in 1 year 75.0% 95.1% 87.2% 89.5% >140/90 x3 in 3 years 67.3% 98.2% 94.4% 87.0% Billing data: Any HTN billing code* 56.1% 94.9% 83.5% 82.3% HTN billing code x2 in 1 year 41.1% 97.8% 89.8% 78.1% HTN billing code x3 in 3 years 33.9% 98.7% 92.2% 76.3% * Billing code = ICD Billing data analysis limited to 883 patients

14 Results - Validation Combination Algorithms: Sensitivity Specificity PPV NPV CPP or > 140/90 ever 91.7% 74.9% 62.1% 95.2% CPP or > 140/90 ever or HTN bill x1 CPP or > 140/90 ever or HTN bill x3 in 3 years 93.2% 67.0% 56.7% 95.5% 92.5% 68.3% 57.6% 95.2% CPP or >140/90 x3 in 3 years 82.0% 98.2% 95.3% 92.4% CPP or >140/90 x3 in 3 years or HTN bill x1 CPP or >140/90 x3 in 3 years or HTN bill x3 in 3 years 87.5% 93.2% 85.7% 94.1% 84.6% 97.0% 92.9%% 93.2% Next step: combining with antihypertensive prescriptions

15 Next Steps: Implications for Quality Martirosyan et al. BMC Health Services Research :137 Identification of HTN in Dutch primary care patients with comorbid diabetes: avg sbp > 140 in past 6 months: 85% sensitivity diagnosis in problem list: 47% sensitivity Search based on diagnostic code identified only 21% of uncontrolled patients, but search based on sbp identified 88%

16 Choosing an algorithm: What s the goal? Want to send a letter to your hypertensive patients? PPV: CPP search or search for multiple billing codes or elevated BP measurements Want to assess hypertension utilization? Sensitivity: CPP search or search for single billing code or elevated BP measurements Need to consider patients who are not recognized / diagnosed / treated

17 Conclusions EMR-based quality assessment requires validation Diagnostic and/or billing fields in EMR charts do not show the whole picture for HTN How patients are identified has implications for quality assessment and quality improvement Best algorithm depends on purpose

18 Thank you Questions/comments? noah.ivers at utoronto.ca

19 Additional info slides

20 Methods Manual Chart Abstraction 5% random sample = 969 charts from first 17 family physicians in EMRALD Convenience sample of physicians, but heterogeneous:» 42% rural» 29% female» 20.5 years in practice (SD 10)» 7.4 years on EMR (SD 7.3)» all but one in group practice

21 Previous Validation Studies Using EMRALD Validation of administrative data algorithms for ischemic heart disease, myocardial infarction Chronic Dis Can. 2010;30(4):141-6, Can J Cardiol. 2010;26(7):e Validation of automated ways to identify patients with diabetes, ischemic heart disease within the EMR J Clin Epidemiol Apr;64(4):431-5, J Prim Care Comm H. 2011; 2(1):49-53.

22 EMRALD: data structure, de-identification STRUCTURED FIXED ENTRY FORMAT Identifying information Numeric data Predefined list Name Lab results Prescriptions Address Blood pressures Phone number Height Postal code Weight Date of birth Healthcard number UNSTRUCTURED FREE TEXT FORMAT Less likely to contain ID info Likely contains ID info Cumulative patient profiles Progress notes Investigations/diagnostic tests Radiology/pathology reports Consultation letters Hospital discharge summaries

Identifying Patients With Ischemic Heart Disease in an Electronic Medical Record

Identifying Patients With Ischemic Heart Disease in an Electronic Medical Record Original Research Identifying Patients With Ischemic Heart Disease in an Electronic Medical Record Journal of Primary Care & Community Health 2(1) 49 53 The Author(s) 2011 Reprints and permission: sagepub.com/journalspermissions.nav

More information

Karen Tu MD, MSc, CCFP, FCFP Scientist ICES Associate Professor DFCM, University of Toronto Active Staff Toronto Western Hospital FHT

Karen Tu MD, MSc, CCFP, FCFP Scientist ICES Associate Professor DFCM, University of Toronto Active Staff Toronto Western Hospital FHT Validation of administrative data algorithms to determine population prevalence and incidence of Alzheimer's disease, dementia, MS, epilepsy and Parkinson's disease Karen Tu MD, MSc, CCFP, FCFP Scientist

More information

Adherence to Hypertension Visit Protocol Description: % of patients with HTN who are being monitored through follow up visits according to guidelines, based on "days since last BP", which looks back from

More information

Diabetes and Hypertension in Canada: New data from the Canadian Chronic Disease Surveillance System

Diabetes and Hypertension in Canada: New data from the Canadian Chronic Disease Surveillance System 1 Diabetes and Hypertension in Canada: New data from the Canadian Chronic Disease Surveillance System Karen C. Roberts, Cynthia Robitaille, Sulan Dai, Paula Stewart, Glenn Robbins, Chris Waters, Bob McRae

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

NATIONAL SURVEILLANCE OF OSTEOARTHRITIS AND RHEUMTOID ARTHRITIS IN CANADA

NATIONAL SURVEILLANCE OF OSTEOARTHRITIS AND RHEUMTOID ARTHRITIS IN CANADA NATIONAL SURVEILLANCE OF OSTEOARTHRITIS AND RHEUMTOID ARTHRITIS IN CANADA Results from the Canadian Chronic Disease Surveillance System Public Health Agency of Canada, Ottawa, ON October 26, 2017 AAC 2017

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and

& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

MPharmProgramme. Hypertension (HTN)

MPharmProgramme. Hypertension (HTN) MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two

More information

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative 2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6

More information

Blood Pressure Treatment Goals

Blood Pressure Treatment Goals Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Hypertension JNC 8 (2014)

Hypertension JNC 8 (2014) Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

DPV. Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl

DPV. Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl DPV Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl Contents Possible use of DPV Languages Patient data Search for patients Patient s info Save data Mandatory fields Diabetes subtypes ICD 10 Fuzzy date

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate

More information

Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ

Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation

More information

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston

More information

Is Traditional Clinic Blood Pressure Dead?

Is Traditional Clinic Blood Pressure Dead? Royal College of Physicans May 16 th 2017 Is Traditional Clinic Blood Pressure Dead? Professor Bryan Williams MD FRCP FAHA FESC Chair of Medicine UCL Director National Institute for Health Research Biomedical

More information

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care Shari Bolen MD, MPH MetroHealth/Case Western Reserve University 1 Disclosure

More information

Notes Indicate to the group that this patient will be the focus of today s case discussion.

Notes Indicate to the group that this patient will be the focus of today s case discussion. 1 Indicate to the group that this patient will be the focus of today s case discussion. Read out the case authors and their disclosure information. Instructions Fill out prior to the meeting and disclose

More information

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):

More information

Epidemiological Update on Dementia, Including Alzheimer s Disease, in Manitoba:

Epidemiological Update on Dementia, Including Alzheimer s Disease, in Manitoba: epiupdate Epidemiological Update on Dementia, Including Alzheimer s Disease, in Manitoba: - Epidemiology & Surveillance Active Living, Indigenous Relations, Population and Public Health Manitoba Health,

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Lessons from the Development of a Canadian National System of Surveillance

Lessons from the Development of a Canadian National System of Surveillance Lessons from the Development of a Canadian National System of Surveillance NATHALIE JETTÉ MD, MSc, FRCPC Assistant Professor Neurology Hotchkiss Brain Institute Calgary Institute of Population and Public

More information

Blood Pressure Measurement in SPRINT

Blood Pressure Measurement in SPRINT Blood Pressure Measurement in SPRINT Karen C. Johnson, MD, MPH, FAHA Vice Chair, SPRINT Steering Committee University of Tennessee Health Science Center, Department of Preventive Medicine For the SPRINT

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution

More information

What is hypertension?

What is hypertension? HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90

More information

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards

More information

Appendix 1 (as supplied by the authors): Databases and definitions used.

Appendix 1 (as supplied by the authors): Databases and definitions used. Appendix 1 (as supplied by the authors): Databases and definitions used. Table e1: The Institute for Clinical Evaluative Sciences databases used in this study and their descriptions Database Ontario Health

More information

OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee

OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension Ontario Health Technology Advisory Committee May 2012 Background Hypertension in Canada Hypertension occurs when

More information

Jessica Widdifield, PhD. Saturday May 25 th 2013

Jessica Widdifield, PhD. Saturday May 25 th 2013 Jessica Widdifield, PhD Saturday May 25 th 2013 Learning Objectives 2 Disclosures Nothing to disclose 3 Measuring disease burden 4 Measuring disease burden - - - 5 Measuring disease burden 18 Rheumatologists

More information

major public health burden

major public health burden HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang, Chung-Shiuan Chen, Qi Zhao, Jing Chen for CATIS

More information

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:

More information

QUESTION-BY-QUESTION INSTRUCTIONS FOR MMCC HEART FAILURE FINAL DIAGNOSIS FORM (HDX)

QUESTION-BY-QUESTION INSTRUCTIONS FOR MMCC HEART FAILURE FINAL DIAGNOSIS FORM (HDX) QUESTION-BY-QUESTION INSTRUCTIONS FOR MMCC HEART FAILURE FINAL DIAGNOSIS FORM (HDX) HDX, Version A, 09-10-2009 HDX QxQ An MMCC Heart Failure Diagnosis Form (HDX) is completed for each ARIC Heart Failure

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Layered Approaches to Studying Drug Responses

Layered Approaches to Studying Drug Responses Layered Approaches to Studying Drug Responses Brian B Hoffman, MD Chief of Medicine VA Boston Health Care System Professor of Medicine Harvard Medical School Conflict of Interest: US Federal Grant Funding

More information

Nighttime Dosing of Anti-Hypertensive Medications

Nighttime Dosing of Anti-Hypertensive Medications Nighttime Dosing of Anti-Hypertensive Medications Gary E. Rosenthal, MD Professor of Internal Medicine & Health Management & Policy Director, Institute for Clinical and Translational Science Elizabeth

More information

Improvement in Diabetic Care

Improvement in Diabetic Care University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Improvement in Diabetic Care Richard Smith University of Vermont Follow this and additional

More information

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant

More information

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

2017 High Blood Pressure Clinical Practice Guideline

2017 High Blood Pressure Clinical Practice Guideline 2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /

More information

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs

More information

Jeff Perrine FNP C, MS

Jeff Perrine FNP C, MS Jeff Perrine FNP C, MS Identify factors that lead to d long term care of patients Identify patient diagnoses as appropriate in ICD 10 Identify available programs to increase revenue in the primary care

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Chronic Disease Summary: Nunavut (Fiscal Years )

Chronic Disease Summary: Nunavut (Fiscal Years ) Chronic Disease Summary: Nunavut (Fiscal Years 2004 2012) The following chronic disease data was produced using the Canadian Chronic Disease Surveillance System (CCDSS), which is a federal initiative that

More information

Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents

Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents Simonetti G.D. Istituto Pediatrico della Svizzera Italiana Ente Ospedaliero Cantonale e Università

More information

Essential Hypertension Management Considerations By Elaine Lewis, ND

Essential Hypertension Management Considerations By Elaine Lewis, ND Essential Hypertension Management Considerations By Elaine Lewis, ND Elaine Lewis, ND Research Resident, Canadian College of Naturopathic Medicine 1255 Sheppard Avenue East North York, Ontario Back To

More information

Firenze 22 settembre 2007

Firenze 22 settembre 2007 Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non

More information

The Impact of E-Path Technology on the Ontario Cancer Registry. Operations

The Impact of E-Path Technology on the Ontario Cancer Registry. Operations The Impact of E-Path Technology on the Ontario Cancer Registry Pathology LIS Operations Presented at the NAACCR 2002 Cancer Informatics Workshop Toronto, Ontario June 2002 EDI Darlene Dale Manager, Ontario

More information

How Low Do We Go? Update on Hypertension

How Low Do We Go? Update on Hypertension How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016 Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1 Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Understand goal of measurement and definition of accuracy Describe the threats to causal

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process Quality ID #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2018 OPTIONS F INDIVIDUAL MEASURES:

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

2013 Hypertension Measure Group Patient Visit Form

2013 Hypertension Measure Group Patient Visit Form Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part

More information

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes. SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,

More information

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0 Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately

More information

Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D.

Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D. Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D. Chronology of ISDN/Hydralazine ISDN/HYD V-HeFT I BIDIL Sub-group

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

May 2016 CTC/OHIC Measure Specifications

May 2016 CTC/OHIC Measure Specifications Active Patients: Overarching Principles and Definitions Out patients seen by a primary care clinician of the PCMH anytime within the last 24 months. Definition of primary care clinician includes the following:

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2018 OPTIONS F INDIVIDUAL MEASURES:

More information

TEAMcare at The Polyclinic: Collaborative Care for Diabetes and Depression

TEAMcare at The Polyclinic: Collaborative Care for Diabetes and Depression TEAMcare at The Polyclinic: Collaborative Care for Diabetes and Depression Michael J. Tronolone, MD, MMM CMO, The Polyclinic Seattle, WA April 3, 2014 1 The Multi-Condition Patient JAMA, April 7, 2010

More information

DIABETES MORTALITY IN NOVA SCOTIA FROM 1998 TO 2005: A DESCRIPTIVE ANALYSIS USING BOTH UNDERLYING AND MULTIPLE CAUSES OF DEATH

DIABETES MORTALITY IN NOVA SCOTIA FROM 1998 TO 2005: A DESCRIPTIVE ANALYSIS USING BOTH UNDERLYING AND MULTIPLE CAUSES OF DEATH DIABETES MORTALITY IN NOVA SCOTIA FROM 1998 TO 2005: A DESCRIPTIVE ANALYSIS USING BOTH UNDERLYING AND MULTIPLE CAUSES OF DEATH Alison Zwaagstra Health Information Analyst Network for End of Life Studies

More information

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center Adolescent Hypertension Roles of obesity and hyperuricemia Daniel Landau, MD Pediatrics, Soroka University Medical Center Blood Pressure Tables BP standards based on sex, age, and height provide a precise

More information

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

Supplemental Table 1. Study design and participant characteristics.

Supplemental Table 1. Study design and participant characteristics. Supplemental Table 1. Study design and participant characteristics. Study ID Study Design; Total No. of Participants Mean age at Parity Participant Selection Criteria Country; Year (PE/no PE) Index Pregnancy

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information